FMT for Patients With IBS With Fecal and Mucosal Microbiota Assessment
Key facts
- Who runs it
- Chinese University of Hong Kong
- Where
- Hong Kong1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 56 people enrolled
- Started
- 12 Apr 2017
- Ended
- 16 Dec 2023
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- Fecal Microbiota Transplantation
- Sham
- Fecal and Mucosal Microbiota Assessment
- Record updated
- 22 August 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Patients are aged 18 or above
- Patients have a diagnosis of IBS consistent with the Rome III criteria (13)
- Patients did not have adequate relief of global IBS symptoms and of IBS-related bloating at both the time of screening and the time of randomization
- Patients had undergone clinical investigations with colonoscopy within five years of recruitment
- Patients with written informed consent form provided
Who cannot take part
- Patients have previous abdominal surgery (other than cholecystectomy or appendectomy)
- Patients have used antibiotic therapy or anti-inflammatory drugs within the past 7 days
- Patients have a history of inflammatory bowel disease or gastrointestinal malignancy
- Patients have human immunodeficiency virus infection
- Patients have a history of psychiatric illness (mania and schizophrenia)
- Patients have anxiety defined by having a Generalized Anxiety Disorder 7 (GAD7) score > 10
- Patients have active infection at the time of inclusion
- Patients have renal disease manifested by 1.5 times the ULN of serum creatinine or blood urea nitrogen level
- Patients have hepatic disease manifested by twice the upper limit of normal (ULN) for any of the following liver function tests: alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, or total bilirubin (except in isolated elevation of unconjugated bilirubin
- Patients have diabetes mellitus manifested by HbA1C > 6.5%
- Patients have abnormal thyroid function manifested by values of serum Sensitive Thyroid Stimulating Hormone and serum free T4 fall outside the reference range which is not controlled by thyroid medications
- Patients have constipation predominant IBS (according to the definition of Rome III criteria)
- Patients have depression defined by having a Patient Health Questionnaire-9 (PHQ-9) score > 15
- Patients have any other organic causes that can explain the symptoms of IBS
- Current pregnancy
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Irritable bowel syndrome (IBS) is a common functional bowel disorder of the gastrointestinal tract affecting up to 20 percent of the adolescent and adult populations. It is characterised by abdominal pain, irregular bowel habits, altered stool consistencies and bloating, and is associated with impaired quality of life. IBS can be categorised into diarrhoea predominant type (IBS-D), constipation predominant type (IBS-C), and mixed type (IBS-M). Fecal microbiota transplantation (FMT) defined as infusion of feces from healthy donors to affected subjects has shown impressive results with high cure rates in patients with recurrent clostridium difficile infections. The investigators propose a randomised, placebo-controlled trial of FMT in patients with IBS.
The 2 groups in the trial
- Fecal Microbiota TransplantationTreatment being tested
FMT infusion and Fecal and Mucosal Microbiota Assessment
Treatment: Fecal Microbiota Transplantation and Fecal and Mucosal Microbiota Assessment
- Sham infusionSham treatment, for comparison
Infusion with sham and Fecal and Mucosal Microbiota Assessment
Treatment: Sham and Fecal and Mucosal Microbiota Assessment
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomised, Placebo-controlled Study on Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome With Fecal and Mucosal Microbiota Assessment
- Publications
- Randomised clinical trial: Faecal microbiota transplantation for irritable bowel syndrome with diarrhoea.Alimentary pharmacology & therapeutics, 2023
- Record updated
- 22 August 2024